NCT Number: NCT01737229
Efficacy and the Safety Study of RD94 in Patients With Endodontic Care
TRIAL TITLE Open trial, not randomized study evaluating the efficacy and the tolerance of RD94 in patients needing endodontic care, medical device class III.
SPONSOR:
SEPTODONT, 58 rue de Pont de Créteil, 94107 Saint Maur des Fossés cedex Tel : + 33 1-49-76-74-26, Fax. : + 33 1- 49-76-71-91
Reference protocol: 09/001
PRODUCT NAME: Biodentine™ (RD94)
MEDICAL DEVICE:
Class: Bioactive dental substitute (Tricalcium silicate) Dose: not applicable Application : one single time
DEVELOPMENTAL PHASE: not applicable (medical device class III)
Looking for future studies?
Notify MeKey information
Age range
3 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Cabinet de Chirurgie Dentaire rue Saint Didier, Paris, France
About this study
METHODOLOGY:
This multi-centre and open-label study comprises six groups corresponding to the six indications tested. No placebo or reference product is involved. No randomization is required as the indication will define the patient selection.
The six indications studied are:
- Direct pulp capping following carious pulp exposure
- Direct pulp capping following dental trauma injury to healthy pulp (partial pulpotomy)
- Repairing perforated root canals and/or the pulp chamber floor
- Retrograde endodontic surgery
- Pulpotomy in primary molars
- Apexification
Study start: October 2009
Inclusion period: 1/10/2009 to 30/06/2011
Study duration: 2 years
OBJECTIVES:
The trial objective is to illustrate the clinical efficacy and tolerance of RD94 in the indications described.
Primary objective:
The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 6 month follow-up.
Secondary objective:
The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.
TRIAL POPULATION AND NUMBER OF PATIENTS:
60 patients in three French study centers, 10 per indication studied. Depending on the indication, children (from 3 years onwards), and/or adults will be included.
DURATION OF TREATMENT:
The product is applied on D0 (Inclusion) of the study. The follow-up period includes 2 years with six visits: Visit1 - Week 1, Visit 2 - Month 1, Visit 3 - Month 3, Visit 4 - Month 6, Visit 5 - Year 1, Visit 6 - Year 2.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- provide signed, informed consent.
- be affiliated to social security. criteria for the corresponding indication: Direct pulp capping following carious pulp exposure - children (6 to 18 years) + adults
- Symptomatic or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy - children (6 to 18 years) + adults
- Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
Repairing perforated root canals and/or the pulp chamber floor - adults
- Iatrogenic perforation of the pulpal floor, with or without LEO.
- Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
- Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO.
Retrograde endodontic surgery - adults
- Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
- Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option.
Pulpotomy in primary molars - children ( 3 to 12 years )
- Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
- Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years.
Apexification - children (7 to 18 years) + adults
- Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
- Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
- Apical Root Resorption
Exclusion criteria
- History of malignancy in the last 5 years.
- Systemic disease not stabilized within 1 month before the Inclusion Visit or judged by the investigator to be incompatible with the study or condition incompatible with the frequent assessments needed by the study.
3 Risk A cardiopathies 4. Known hypersensitivity to one of the components of the study or procedural medications.
- Presence or history of severe systemic allergy. 6. Presence or history of drug addiction or alcohol abuse. 7. Patient who has participated in a clinical trial with a new active substance during the month before study entry.
- Participation in another clinical study at the same time as the present study.
- Known pregnancy or lactation at study entry.
Exclusion criteria
for each indication : Direct pulp capping following carious pulp exposure
- Chronic irreversible pulpitis
- Pulp necrosis
- Anterior or saliva-contaminated tooth pulp exposure
- Accidental exposure occurring during non-retentive prosthetic preparation Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy
- Pulp exposure period > 72 hours
- Crown-root fracture
- Pulpal necrosis with or without periapical disease(LEO)
Repairing perforated root canals and/or the pulp chamber floor
- Supracrestal iatrogenic perforation
- Inadequate periodontal support
- Loss of tooth structure (Coronal decay and/or concomitant root decay) compromising the tooth's maintenance on the dental arch) Retrograde endodontic surgery
- Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, when a working coronal restoration is either missing or presents microleakage
- Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when surgical treatment does not offer a more favorable risk-benefit ratio than the orthograde retreatment option
- Insufficient periodontal support, endo-periodontal lesion
- Coronal decay and/or concomitant root decay compromising the tooth's maintenance on the dental arch
- Maxillary intrabony lesion of suspected non-endodontic origin
Pulpotomy:
- Temporary molar expected to begin exfoliation within 24 months.
- Molar presenting signs of irreversible pulp disease - spontaneous pain
Treatment and study plan
Primary outcomes
-
Efficacy
Time frame: 3 months
The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 3 month follow-up.
Secondary outcomes
-
Long term efficacy and safety
Time frame: 2 years
The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.
Sponsors and collaborators
Lead sponsor
Ascopharm Groupe Novasco
Other
Collaborators
- AscoPharm is conducting the study under the responsibility of SEPTODONT
Registry information
Official study title
Open Trial, Not Randomized Study Evaluating the Efficacy and the Tolerance of RD94 in Patients Needing Endodontic Care, Medical Device Class III
Acronym: RD94
Important dates
- Study start
- 2010
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Nov 29, 2012
- Registry last updated
- Jul 24, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Clinical and Radiological Evaluation of Dental Autotransplantation in the Anterior Region in Young Patients
NCT07314580
Fractures, Avulsion, Fractures, Bone
Barcelona, Barcelons, Spain
View Trial DetailsTraumatic Dental Injuries Treatment and Oral Health Related to Quality of Life
NCT03720925
Quality of Life, Stomatognathic Diseases
Nova Friburgo, Rio de Janeiro, Brazil
View Trial DetailsThe Cortical Shield for Facial Bone Reconstruction
NCT04827693
Alveolar Bone Loss, Bone Diseases
Los Angeles, California, United States
View Trial DetailsAcute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area
NCT00995319
Deglutition Disorders, Digestive System Diseases
Trondheim, Norway
View Trial Details